2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. STK33

STK33

Serine/threonine kinase 33

Serine/Threonine Kinase 33 (STK33) plays a pivotal role in cancer cell proliferation and metastasis by phosphorylating serine and threonine residues on proteins, thereby regulating crucial cellular processes such as signal transduction, DNA replication, cell differentiation, proliferation, apoptosis, and tumor development. STK33 is overexpressed in various cancers, including pancreatic, lung, and liver cancers, compared to non-cancerous tissues. Notably, STK33 activates the PI3K/Akt/mTOR signaling pathway in gastric cancer, promoting metastasis. Additionally, the STK33/ERK2 signaling pathway contributes to the tumorigenesis of colorectal cancer by phosphorylating ERK2, enhancing its activity and promoting cancer progression. STK33's involvement in cancer development underscores its importance in oncology research.[1][2].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13495
    ML281
    		Inhibitor 99.91%
    ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM.
    ML281
  • HY-162565
    CDD-2807
    		Inhibitor
    CDD-2807 is an inhibitor for serine/threonine kinase 33 (STK33) with IC50 of 9.2 nM. CDD-2807 exhibits no significant toxicity in mice and can cross the blood-testis barrier without accumulating in the brain. CDD-2807 induces a reversible contraceptive effect and has potential for the development of the male contraceptive.
    CDD-2807
  • HY-13498
    BRD-8899
    		Inhibitor
    BRD-8899 is a STK33 inhibitor, with an IC50 of 11 nM.
    BRD-8899
  • HY-13497
    STK33-IN-1
    		Inhibitor
    STK33-IN-1 (compound 1) is a STK33 inhibitor, with an IC50 of 7 nM.
    STK33-IN-1
Cat. No. Product Name / Synonyms Application Reactivity